Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 888

Document Document Title
WO/2021/069570A1
Compounds and compositions for the activation of SERCA2a are disclosed. In particular, provided are compounds that act as predominantly pure or pure SERCA2a activators while only moderately inhibiting the Na+/K+ ATPase. In general, the d...  
WO/2020/264495A1
Provided herein is a compound of Formula (1-I): or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R11a, R11b, R16a, R16b, R19, R18, X, q, r, s, t, u, and n are defined herein. Also provided here...  
WO/2020/243488A1
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...  
WO/2020/222717A1
The invention is related to an AG-08 coded novel structured molecule having cytotoxic features against cancer cells. The aim of the invention is to primarily synthesize the astragenol (AG) molecule from cycloastragenol (CA) and then from...  
WO/2020/187658A1
The invention relates to a process for the preparation of fulvestrant 3- boronic, comprising the transformation of the compound of formula (IV) into the compound of formula (III). The intermediate of formula (III) also forms part of the ...  
WO/2020/169643A1
The present invention relates to the diethylamine salt of 3a- tetrahydropyranyloxy-6a-ethyl-7a-hydroxy-53-cholanic acid (I), which is a new intermediate in the synthesis of obeticholic acid, to the use of said diethylamine salt in the sy...  
WO/2020/168283A1
The present disclosure relates to methods of managing cancer by modulating/inhibiting cap methyltransferase enzyme. The modulation/inhibition is carried out by pharmacological or biological inhibitors, including but not limited to compou...  
WO/2020/119836A8
A process for preparing obeticholic acid, wherein the 7-keto-litocholic acid amide of formula (II), where R1, R2 are a C1-C6 n-alkyl, or together a C5-C6 cycle and the protecting group on the hydroxyl in position 3 is a carbamoyl with th...  
WO/2020/132504A1
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...  
WO/2020/128514A1
2-Fluorinated bile acid compounds of general formula (I) wherein at least one of R1 and R2 represents F and the other is chosen 3 from H and F and wherein R3 is as defined herein; are of use in the treatment and prevention of neurodegene...  
WO/2020/119836A1
A process for preparing obeticholic acid, wherein the 7-keto-litocholic acid amide of formula (II), where R1, R2 are a C1-C6 n-alkyl, or together a C5-C6 cycle and the protecting group on the hydroxyl in position 3 is a carbamoyl with th...  
WO/2019/161211A3
Methods useful for reducing or preventing hepatic steatosis and NASH are provided herein. Such methods may comprise administering to a subject in need thereof an FXR agonist in combination with an amount of a branched amino acid in free ...  
WO/2020/025942A1
Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic ...  
WO/2019/224790A2
The present invention relates to fulvestrant prodrugs of formula II and process for the preparation thereof. The present disclosure also relates to pharmaceutical composition of fulvestrant prodrugs and method of treatment using the same.  
WO/2019/126741A1
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...  
WO/2018/103626A1
The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nerv...  
WO/2018/085623A1
Disclosed are methods of treating or reducing the occurrence of a steatohepatitis disorder. The disorder may include, for example, NASH, parenteral nutrition associated liver disease (PNALD), or genetic forms of liver disease. The method...  
WO/2018/071544A1
This document relates to an abiraterone derivative, 2-(((3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)- 2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]ph enanthren-3-yl)oxy)-2-oxoacetic acid (ABOA). This document also...  
WO/2018/068021A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2018/060280A1
Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstitu...  
WO/2018/054300A1
Provided is a crystalline form cholic acid derivative free alkali, a preparation method therefor and an application. The chemical name of the cholic acid derivative free alkali is (5R)-5-((2R)-2-((3R,5S,6R,7R,10S,13R)-6-ethyl-3,7-dihydro...  
WO/2018/035079A1
A class of cyanosteroid compounds that efficiently inhibit ghrelin acylation by ghrelin O-acyltransferase. The compounds have a steroid scaffold with α,β-unsaturated ketone in the A ring position such an a-cyanoenone. Exemplary compoun...  
WO/2017/207648A1
The invention relates to a process for the preparation of obeticholic acid and derivatives thereof comprising: (a) olefination of a compound of formula (II) or a salt or solvate thereof to obtain a compound of formula (III) or a salt or ...  
WO/2017/199033A1
The invention relates to compounds of general formula (I): wherein: R1,R2, R3, R4, R5, R6 and Y are as defined herein. The compounds are intermediates in the synthesis of synthetic bile acids which are useful in the treatment of conditio...  
WO/2017/199039A1
The invention relates to a process for preparing a compound of general formula (Ia): wherein R2, Y, R4 and R5 are as defined herein. The invention also relates to certain compounds per se. The compounds are intermediates in the synthesis...  
WO/2017/192668A1
Disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery. In particular, disclosed are methods for identifying a pregnant female who is susceptible to spontaneous preterm delivery based o...  
WO/2017/150723A1
Algae that generates a sterol and a sterol production method that uses the algae. According to the present invention, a sterol is produced by culturing algae, such as strain AJ7867 (FERM BP-22304) and strains derived therefrom, that has ...  
WO/2017/149091A1
The invention relates to a process for the preparation of 11 -methylene steroids through selective olefination of the ketone at position 11. The resulting products are useful intermediates in the preparation of several pharmaceutically a...  
WO/2017/149052A1
The invention pertains to a process for producing a compound of formula (11) wherein R7 and R8 are each independently selected from H, halogen, alkyl, aryl, or alkylaryl, R42 is H or a protective group, R43 is H or R3, wherein R3 is a pr...  
WO/2017/137931A1
The present application relates to amine salt of obeticholic acid. Specifically, the present application relates to (S)-α-methylbenzylamine and diethylamine salt of obeticholic acid. The present application also relates to a process for...  
WO/2017/112904A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/111979A1
The present application relates to crystalline forms A, D, F, G and I of obeticholic acid. These crystalline forms are useful in the production of Obeticholic acid (in particular its purification), which is a drug useful for the treatmen...  
WO/2017/112909A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2017/112902A1
The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The s...  
WO/2016/173397A1
The present invention relates to a cholic acid derivative, and a preparation method and a medical use thereof. In particular, the present invention relates to a cholic acid derivative with the structure of formula (I), a stereoisomer, or...  
WO/2016/154203A1
Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2. In one embodiment, a cytotoxic compound...  
WO/2016/109471A1
Bufalin phosphate prodrugs are provided herein, as well as methods for their use as small molecule inhibitors of steroid receptor coactivator (SRC) family proteins. Methods for using bufalin phosphate prodrugs in treating or preventing c...  
WO/2016/102775A1
The present invention accordingly provides novel compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the claims. The invention further relates to their in treatment or prevention of steroid hormone dependent diseases or ...  
WO/2016/102776A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prev...  
WO/2015/075693A8
The invention relates to a process for the synthesis of (11β,17α)-17-acetoxy-11 - methyl-19-norpregn-4-en-3,20-dione of formula (I) using the compound of formula (II) as starting material as well as the intermediates of the process.  
WO/2015/121840A1
The present invention relates to a process for the synthesis of compounds of formula (I), (I) wherein the meaning of R is dimethylamino or acetyl group, using the compound of formula (III) or (IV), wherein the meaning of R' is dimethylam...  
WO/2015/092647A1
The present invention relates to a new stereoselective process for the synthesis of 17(α)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(α)-17-acetyl-17-hy droxy-estr-4-e...  
WO/2015/091958A1
The present invention relates to novel compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising PEG moieties, useful for binding cells, as well as uses and compositions related thereto. The compounds are u...  
WO/2015/091953A1
The present invention relates to the use compounds comprising two or more hydrophobic domains and a hydrophilic domain comprising a polyethylene glycol (PEG) moiety for stabilization of a cell, and methods related thereto.  
WO/2015/075693A1
The invention relates to a process for the synthesis of (11 β,17α)-17-acetoxy-11 - inethyl-19-norpregn-4-en-3,20-dione of formula (I) using the compound of formula (II) as starting material as well as the intermediates of the process.  
WO/2015/049637A1
The present invention relates to a new process for the synthesis of compounds of formula (I) (wherein the meaning of R is dimethylamino or acetyl group) using the compound of formula (II) (wherein the meaning of R is dimethylamino or 2-m...  
WO/2014/207311A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R2, R3, R4, R7 and R8 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in trea...  
WO/2014/207309A1
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R6 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD and in treatment or preve...  
WO/2014/091158A1
The present invention relates to testosterone derivatives of formula (I): in which n is an integer between 1 and 10 and Y is an activated or ready-to-be-activated group which enables the formation of an amide bond with a primary amine of...  
WO/2013/192097A1
The present invention relates to obeticholic acid: or a pharmaceutically acceptable salt, solvate or amino acid conjugate thereof. Obeticholic acid is useful for the treatment or prevention of a FXR mediated disease or condition, cardiov...  

Matches 1 - 50 out of 888